486 related articles for article (PubMed ID: 19738122)
21. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Cohen EE; Subramanian J; Gao F; Szeto L; Kozloff M; Faoro L; Karrison T; Salgia R; Govindan R; Vokes EE
Clin Lung Cancer; 2012 Mar; 13(2):123-8. PubMed ID: 22100149
[TBL] [Abstract][Full Text] [Related]
22. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
[TBL] [Abstract][Full Text] [Related]
23. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
24. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in non small cell lung cancer.
Sandler A
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A; Tiseo M; Boni L; Vincent AD; Passalacqua R; Buti S; Amoroso D; Camerini A; Labianca R; Genestreti G; Boni C; Ciuffreda L; Di Costanzo F; de Marinis F; Crinò L; Santo A; Pazzola A; Barbieri F; Zilembo N; Colantonio I; Tibaldi C; Mattioli R; Cafferata MA; Camisa R; Smit EF
J Clin Oncol; 2012 Dec; 30(36):4501-7. PubMed ID: 23109689
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
28. First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy.
Chargari C; Pacaut C; Le Moulec S; Moriceau G; Moussaid Y; Rivoirard R; Dulou R; Jacob J; Guy JB; Bauduceau O; Ceccaldi B; Védrine L; Fournel P; Magné N
Anticancer Drugs; 2013 Aug; 24(7):736-42. PubMed ID: 23542752
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
30. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
31. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
32. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
33. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Bearz A; Garassino I; Tiseo M; Caffo O; Soto-Parra H; Boccalon M; Talamini R; Santoro A; Bartolotti M; Murgia V; Berretta M; Tirelli U
Lung Cancer; 2010 May; 68(2):264-8. PubMed ID: 19632738
[TBL] [Abstract][Full Text] [Related]
34. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
37. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.
Soria JC; Smit E; Khayat D; Besse B; Yang X; Hsu CP; Reese D; Wiezorek J; Blackhall F
J Clin Oncol; 2010 Mar; 28(9):1527-33. PubMed ID: 20159815
[TBL] [Abstract][Full Text] [Related]
38. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
39. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.
Leon L; Vázquez S; Gracia JM; Casal J; Lazaro M; Firvida JL; Amenedo M; Santome L; Macia S
Expert Opin Pharmacother; 2012 Jul; 13(10):1389-96. PubMed ID: 22630129
[TBL] [Abstract][Full Text] [Related]
40. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]